Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-07-14 10:01:21

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.

zacks.com - 2026-07-10 18:51:09

CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.

fool.com - 2026-07-10 13:00:00

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

fool.com - 2026-07-08 05:45:00

CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.

zacks.com - 2026-07-07 19:01:18

CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.

fool.com - 2026-07-07 13:45:00

Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.

schaeffersresearch.com - 2026-07-07 13:05:50

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.

fool.com - 2026-07-07 10:36:52

CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.

fool.com - 2026-07-06 07:35:01

CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.

fxempire.com - 2026-07-03 17:05:13

Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.

seekingalpha.com - 2026-07-03 12:14:32

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

fool.com - 2026-07-03 08:37:20

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com - 2026-06-30 10:01:40

CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.

fool.com - 2026-06-27 06:00:03

CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move from the prior day.

zacks.com - 2026-06-26 18:50:22

Exploring some of the top bargains in a multi-trillion-dollar industry.

fool.com - 2026-06-22 08:45:00

The opportunity is enormous, but uncertainty remains.

fool.com - 2026-06-18 09:00:00

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $53.09, indicating a +2.06% shift from the previous trading day.

zacks.com - 2026-06-17 18:50:30

They have at least one thing in common: An exciting pipeline.

fool.com - 2026-06-17 16:00:00

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

My strategy involves focusing on dividends, growth, and also taking on some calculated risk.

fool.com - 2026-06-17 12:30:00

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-06-16 10:01:19

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.

zacks.com - 2026-06-11 18:51:14

VO is a low-cost ETF offered by Vanguard, providing broad exposure to U.S. mid-cap stocks as defined by CRSP. However, CRSP Indexes allow overlap with the small/large-cap segments, impacting efficiency. As is common for Vanguard ETFs, VO will most likely deliver average category returns year to year, as it has done historically. However, it's not ideal from a fundamentals perspective. This article suggests combining XMHQ and XMMO to create a high-quality portfolio with strong momentum characteristics, potentially allowing for lesser drawdowns and faster recoveries.

seekingalpha.com - 2026-06-11 16:14:52

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.

zacks.com - 2026-06-10 19:01:56

CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 17:02:12

The biotech has won approval for one of the few gene-editing therapies on the market. Several more therapies based on the same science are in the works.

fool.com - 2026-06-08 12:53:00

CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript

seekingalpha.com - 2026-06-04 19:32:53

CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 21:32:00

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-03 12:30:37

CRISPR's Casgevy cements the company as a leader in gene-editing therapies. The company's commercial momentum should build as Casgevy reaches more patients.

fool.com - 2026-06-03 12:30:00

Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene editing-focused biotech.

fool.com - 2026-06-03 03:00:00

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

zacks.com - 2026-06-02 13:10:18

This little-discussed pipeline program could prove to be a big success.

fool.com - 2026-06-01 12:30:00

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-06-01 10:01:31

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

fool.com - 2026-05-31 12:11:48

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Time: 9:55 a.m.

globenewswire.com - 2026-05-28 08:00:00

Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026.

seekingalpha.com - 2026-05-21 17:40:46

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-05-19 10:01:32

Not every high-potential name costs a fortune to step into.

fool.com - 2026-05-19 09:45:00

CRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.

marketbeat.com - 2026-05-15 20:14:05

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 19:50:46

The biotech's innovative platform could pay off.

fool.com - 2026-05-11 16:15:00

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

zacks.com - 2026-05-08 14:21:09

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-05-08 10:01:34

Crispr Therapeutics AG is positioned as a long-term buy-and-hold, underpinned by its pioneering gene editing platform and commercial-stage asset Casgevy. Casgevy revenues fell sequentially, but >500 patients have initiated treatment, supporting a multibillion-dollar opportunity with a large, underpenetrated addressable market. CRSP's pipeline offers near-term catalysts in autoimmune and in-vivo gene editing, with several Phase 1 updates expected later this year.

seekingalpha.com - 2026-05-06 09:12:53

ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT.

globenewswire.com - 2026-05-06 08:30:00

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

zacks.com - 2026-05-05 09:21:14

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.58 per share a year ago.

zacks.com - 2026-05-04 20:30:53

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.

globenewswire.com - 2026-05-04 16:30:00